Showing 3581-3590 of 7768 results for "".
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- Topix Pharmaceuticals Rolls Out Replenix RetinolForte Treatment Serumhttps://practicaldermatology.com/news/topix-pharmaceuticals-rolls-out-replenix-retinolforte-treatment-serum/2458242/Topix Pharmaceuticals is adding Replenix® RetinolForte Treatment Serum to their portfolio of offerings. The serum’s patent-pending, time-released Micropolymer delivery system deposits retinol into t
- Indoor Tanners Exhibit Poor Outdoor Sun Protection Practices Toohttps://practicaldermatology.com/news/indoor-tanners-exhibit-poor-outdoor-sun-protection-practices-too/2458406/Adults who frequently tan indoors aren’t great about protecting their skin outdoors or undergoing skin cancer screening either, according to a new study published online by JAMA Dermatology.
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- Provectus: PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At ESMO 2014https://practicaldermatology.com/news/20140915-provectus_pv-10_clinical_data_on_the_treatment_of_melanoma_to_be_presented_at_esmo_2014/2459120/Provectus Biopharmaceuticals, Inc. will present clinical data on PV-10 at the European Society for Medical Oncology's 2014 Congress (ESMO) in Madrid, Spain. The presentation, titled "Subgroup efficacy in patients receiving intralesional rose bengal t
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Heart Transplant Patients Show Increased Skin Cancer Incidence: Meta-Analysishttps://practicaldermatology.com/news/heart-transplant-patients-show-increased-skin-cancer-incidence-meta-analysis/2470902/Heart transplant (HTx) recipients face a 16% overall risk of developing skin cancer, with squamous and basal cell carcinomas being the most common forms, a new meta-analysis indicated. "Studies have shown that patients who undergo HTx are at an increased risk for developing skin cancer," t
- Advanced Neuroprotein Technique Linked with Improved Aesthetic Resultshttps://practicaldermatology.com/news/advanced-neuroprotein-technique-linked-improved-aesthetic-results/2468758/A study evaluating the use of botulinic neuroprotein combined with low molecular weight hyaluronic acid (LMWHA) and lyophilized amino acids in a single syringe showed enhanced outcomes in aesthetic treatments. The study included patients treated with a single injection session. According t
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t